.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Citi
Boehringer Ingelheim
Queensland Health
Chubb
Baxter
Dow
Fish and Richardson
Express Scripts
UBS

Generated: September 23, 2017

DrugPatentWatch Database Preview

FLOVENT Drug Profile

« Back to Dashboard

Which patents cover Flovent, and when can generic versions of Flovent launch?

Flovent is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in four NDAs. There are sixteen patents protecting this drug.

The generic ingredient in FLOVENT is fluticasone propionate. There are twenty-four drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Summary for Tradename: FLOVENT

Patents:0
Applicants:2
NDAs:4
Bulk Api Vendors: see list44
Clinical Trials: see list27
Patent Applications: see list6,300
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FLOVENT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxosmithkline
FLOVENT
fluticasone propionate
AEROSOL, METERED;INHALATION020548-001Mar 27, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-003May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FLOVENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
FLOVENT
fluticasone propionate
AEROSOL, METERED;INHALATION020548-001Mar 27, 1996► Subscribe► Subscribe
Glaxosmithkline
FLOVENT
fluticasone propionate
POWDER;INHALATION020549-002Nov 7, 1997► Subscribe► Subscribe
Glaxosmithkline
FLOVENT
fluticasone propionate
POWDER;INHALATION020549-001Nov 7, 1997► Subscribe► Subscribe
Glaxosmithkline
FLOVENT
fluticasone propionate
AEROSOL, METERED;INHALATION020548-003Mar 27, 1996► Subscribe► Subscribe
Glaxosmithkline
FLOVENT
fluticasone propionate
AEROSOL, METERED;INHALATION020548-002Mar 27, 1996► Subscribe► Subscribe
Glaxosmithkline
FLOVENT
fluticasone propionate
POWDER;INHALATION020549-003Nov 7, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
AstraZeneca
Johnson and Johnson
Harvard Business School
Federal Trade Commission
Daiichi Sankyo
Mallinckrodt
Express Scripts
Cipla
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot